Search Weight Loss Topics:

Page 1,854«..1020..1,8531,8541,8551,856..1,8601,870..»

Home » Page 1854

Keeping the simple sugar fructose, particularly high-fructose corn syrup, off the menu can help avert health issues including obesity, fatty liver disease and type 2 diabetes. Fructose accelerates the conversion of sugar to fat, researchers noted. Their JAOA review summarized the results of several carefully controlled studies, finding a link between high consumption of sugar, in particular fructose, and increased fat synthesis in the liver.

"Fructose provides no nutritional value and isn't metabolized in the brain. Your body converts it to fat, but doesn't recognize that you've eaten, so the hunger doesn't go away," explains Tyree Winters, DO, an osteopathic pediatrician focused on childhood obesity. "Many young patients tell me they're always hungry, which makes sense because what they're eating isn't helping their bodies function."

Overfed and undernourished

The JAOA review identified fructose as a particularly damaging type of simple sugar. Compared to glucose, which metabolizes 20 percent in the liver and 80 percent throughout the rest of the body, fructose is 90 percent metabolized in the liver and converts to fat up to 18.9 times faster than glucose.

HFCS is found in 75 percent of packaged foods and drinks, mainly because it is cheaper and 20 percent sweeter than raw sugar. Fructose turns on the metabolic pathways that converts it to fat and stores it in the body, adding weight. At the same time, the brain thinks the body is starving and becomes lethargic and less inclined to exercise.

"If we cut out the HFCS and make way for food that the body can properly metabolize, the hunger and sugar cravings fade. At the same time, patients are getting healthier without dieting or counting calories," Dr. Winters says. "This one change has the potential to prevent serious diseases and help restore health."

Fighting back

Once people have put on a significant amount of weight and developed eating habits that rely on packaged and processed foods with HFCS, change can be daunting. Historically, physicians have told patients to restructure their diet and start exercising heavily, with a plan to check back after a month or more. That approach rarely works, as seen by the ever-growing obesity epidemic.

Instead, Dr. Winters suggests checking blood work about two weeks after patients agree to begin limiting their sugar intake to help patients see clear benefits for their effort.

"That single change in diet improves metabolic results in less than two weeks. Imagine the power of doing a 'before and after' comparison with a patient, so they can see for themselves that their health is improving. Seeing those results, instead of just stepping on a scale, can motivate them to keep going," Dr. Winters explains.

AboutThe Journal of the American Osteopathic AssociationThe Journal of the American Osteopathic Association (JAOA)is the official scientific publication of the American Osteopathic Association. Edited by Robert Orenstein, DO, it is the premier scholarly peer-reviewed publication of the osteopathic medical profession. TheJAOA's mission is to advance medicine through the publication of peer-reviewed osteopathic research.

View original content with multimedia:http://www.prnewswire.com/news-releases/overweight-children-and-adults-get-significantly-healthier-and-quickly-with-less-sugareven-if-they-dont-lose-weight-300500335.html

SOURCE American Osteopathic Association

Originally posted here:
Overweight Children and Adults Get Significantly Healthier and Quickly With Less Sugar--Even If They Don't Lose Weight - PR Newswire (press release)

Read More..

EnteroMedics Inc (NASDAQ:ETRM) stock was up over 17% in Mondays after-hours trading session, to end at $4.49, after the company announced a loss of $6.8 million in its second quarter. Revenues came in at $93,000 less than what was expected. However, on a per-share basis, the St. Paul, MN-based, medical device company lost (-$0.91) which beat street estimates by $0.02.

Importantly, implantations of the companys lead revenue generator, the vBloc, was up over 83% from the same quarter last year. For the six months ended June 30, 2017, the Company placed 50 units, primarily from the vBloc Now program, a 72% increase compared to 29 units for the same period in 2016. As of June 30, 2017, the Company had cash, cash equivalents and short-term investments totaling $11.2 million and it had no debt.

EnteroMedics Inc (NASDAQ:ETRM) is a developer of medical devices that cater to the weight-loss market. The company developed the FDA-approved vBloc neurometabolic therapy. The vBloc therapy is delivered by a pacemaker-like device called the Maestro Rechargeable System. This device is designed to help patients feel full and eat less by intermittently blocking hunger signals on the vagus nerve thereby allowing patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. The vBloc Therapy is a non-anatomy altering or restricting, and is reversible. therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.

Bariosurge Inc. was recently acquired by EnteroMedics Inc (NASDAQ:ETRM) which gave the company an additional revenue stream originating from the weight-loss market. Bariosurge is the developer of the Gastric Vest System. The Gastric Vest is being developed as a minimally invasive, laparoscopically implanted medical device for weight loss in morbidly obese patients. The device wraps around the stomach, emulating the effect of conventional weight-loss surgery, and is intended to reduce the size of the stomach without permanently changing ones anatomy.

EnteroMedics Inc (NASDAQ:ETRM) continues to address the primary cause of drag on the stock price a lack of coverage by major insurance companies. It is important to remember that the stock blasted over 700% on the news that the company had two new facilities agree to be used for device implantation. It appears the market will reward the company for any advancement of its device into the medical mainstream.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without anyguarantees of accuracy.

Dont miss out! Stay informed on $ETRM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.View all posts by Steve Clark

Read the original here:
EnteroMedics Inc (NASDAQ:ETRM) After-Hours News Hits Stock - StockNewsUnion

Read More..

Millions of people drink diet sodas because of the belief that they help with weight loss. A new study has shown this conviction is a myth: the beverages actually promote weight gain. In addition, they are also linked to heart disease, high blood pressure and diabetes.

In the first few decades after artificial sweeteners debuted on the market, they were viewed as an easy method of reducing daily calorie intake. Products containing sucralose, aspartame, and saccharin, sold under the brand names of Splenda, Equal and Sweet N Low, were wildly popular. Diet sodas and desserts labeled sugar-free were eagerly snatched up at supermarkets because they were considered by many as a guilt-free way to indulge a sweet tooth.

While products containing artificial sweeteners continue to be widely used, in recent years, as research has indicated they may have adverse health effects, Americans are increasingly worried about their safety. A new review of studies published in the Canadian Medical Association Journal gives more cause for concern. It examined the chemicals long-term effects on health, and the results werent pretty.

Scientists at the University of Manitobas George & Fay Yee Centre for Healthcare Innovation looked at 37 studies that followed 406,000 users of artificial sweeteners for an average of 10 years. Seven of the studies were randomized clinical trials, the gold standard in research, which included 1,007 people who were followed for approximately six months.

Analysis of the data failed to prove either a short-term or a long-term benefit. The six-month trials didnt show that artificial sweeteners had a consistent weight loss effect. Moreover, the 10-year observation studies revealed links to modest gains in weight and body mass index, as well as increased waistline size, a problem associated with a heightened risk of several chronic diseases. The longer studies also showed an ominous connection to somewhat higher likelihoods of obesity, heart disease, diabetes and other health problems.

Despite the fact that millions of individuals routinely consume artificial sweeteners, relatively few patients have been included in clinical trials of these products, said author Ryan Zarychanski, assistant professor, Rady Faculty of Health Sciences, University of Manitoba. We found that data from clinical trials do not clearly support the intended benefits of artificial sweeteners for weight management.

Caution is warranted until the long-term health effects of artificial sweeteners are fully characterized, said lead author Meghan Azad, assistant professor, Rady Faculty of Health Sciences, University of Manitoba. Given the widespread and increasing use of artificial sweeteners and the current epidemic of obesity and related diseases, more research is needed to determine the long-term risks and benefits of these products.

In an interview with Olive Oil Times, Carolyn Dean, medical doctor and naturopath, didnt mince words in giving her opinion about the research. She is a Medical Advisory Board Member of the Nutritional Magnesium Association.

This study, which exposes the false claims of synthetic sweeteners, should have the industry quaking in its boots. It was extremely comprehensive, including 11,774 citations. The results were the opposite of what the synthetic sweetener industry advertises. Every practitioner who recommends synthetic sweeteners should be informed that they are harming their patients.

We have to go back to a simple dietary restriction of sugars to achieve health rather than substituting synthetic sweeteners. These chemicals may be harmful in themselves and also give people a false sense that using them permits cheating with high caloric treats.

See the article here:
Diet Soda Linked to Weight Gain, Not Weight Loss - Olive Oil Times

Read More..

I've accepted that many people don't want to meet with a dietitian. It's assumed that we're going to suggest eating bland, healthy, nutritious food, and avoiding all the tasty treats. Quite frankly, sometimes a version of that is true, causing a vicious cycle to occur. Clients are annoyed that they must give up the fun foods, and every follow-up appointment is a discussion about how they feel deprived and can't imagine another day without their drinks, sweets and fries.

This pattern leads to stress. People judge food as good and bad, are overwhelmed about food choices, feel frustrated that they can't eat treats and sweets and guilty when they eat something they're not supposed to. Everything about food, nutrition and health becomes stressful and unpleasant.

It's a tricky situation because dietitians truly don't want people to excessively eat sweets, fried foods and other goodies or drink too much alcohol or sweetened beverages. We want to support individuals in creating long-term behavior change and enjoying the experience. Typically, if people think they're on a diet, it rarely sticks for the long term.

To achieve the goal of nutrition, behavior change requires a shift in perspective.

Psychologist Kelly McGonigal's TED talk, How to make stress your friend, sheds light on how one's perception of stress can be a game changer in creating sustainable behavior change.

She highlights a study in which researchers took close to 30,000 names from the 1998 National Health Interview Survey and looked at how they answered questions related to their stress levels, their perception of stress, and whether they try to reduce their stress. The researchers then used public health records to compare that information with mortality data through 2006. One finding was that neither amount of stress nor perception of stress alone was associated with a higher risk of death. But both of those factors together reporting a lot of stress and believing stress has a large effect on health did increase that risk.

Another study she describes is one in which participants were put in stressful situations and monitored on their physical response. One group was taught in advance to look at stress as positive. For example, they learned that an adrenaline rush helps them perform better. That group experienced fewer negative physical response symptoms. Their perception of stress decreased their internal stress response.

How can this support you in creating new nutrition habits?@body Living:

Here are some common stressful and unpleasant thoughts one can have while starting a healthy eating plan:

I hate being so restricted. How am I going to survive without my favorite food?

I'm not going to be able to have a social life! How am I going to fit in during social situations? What am I going to eat at that party?

I hate this. Why do I have to struggle like this? Why does this have to be so difficult?

This is terrible. I hate vegetables, eating healthy and eating like this. This is never going to work.

I'm hungry, I'm tired, I can't keep a thought. Eating like this feels uncomfortable.

What if you looked at the experience differently? What if you embraced the difficulty of changing your lifestyle and had pleasant thoughts about the new healthy body you could have? What if the stress of it all didn't have to feel so difficult? It's stressful, but that may not be a bad thing.

Some examples to strategize this new perspective:

Set a pleasant tone. You're sitting down for lunch and it's a meal in line with your new healthy lifestyle. The plate is full of vegetables, healthy fats, protein and fiber, and you tell yourself, This is going to make me feel energized, lean and healthy!

Enjoy some treats. When people start eating healthily, they often go all out and eliminate all their favorite foods, leading to deprivation and stress. Enjoy a treat from time to time. Keep it in appropriate proportion and enjoy once or twice a week.

Remember to take a breath. When you're walking into a social situation and aren't sure how to eat, stop for just a moment and take a breath. Find people you enjoy spending time with so you can laugh and have a good conversation. Make the best decisions you can and enjoy the night.

Create tools for success. Often when people go on diets, they undereat and get so hungry they feel physically and emotionally stressed. Caloric deprivation isn't necessary. Have food prepped and planned so you're always prepared. Stay consistent with your meal timing to keep you full and satisfied through the day.@body Living:

Eating better can be quite pleasant. Learning how to view the process to your advantage not only supports you in reaching your goals, but makes the experience so much more enjoyable. McGonigal says, When you choose to view your stress response as helpful, you create the biology of courage. Consider eating healthier as a brave act.

Follow this link:
Changing view on weight loss changes results - Fort Wayne Journal Gazette

Read More..

This is probably one of the hard bits for most people to follow, because it takes discipline. Fasting. But what I can tell you is that fasting does do a lot to improve the HGH output of your body, as well as contributing to your overall longevity.

Food deprivation has been shown to increase the lifespan of mice in lab conditions, as it is. Back in the old days, food shortages were a normal thing. Today, people eat a lot more. Which isnt really a bad thing. You will notice the human race has increased in size overall, ever since the good old 70s. Its one of the reasons why todays movies set in ancient times are really unrepresentative of the overall height and sizes of people back then.

Dont believe me? Take a look at old pictures of say pre-Depression era pictures of the people back then. Or even any 19th century pics if you can find them online. Back then, if you were 6 feet, you were already a giant of sorts.

But the problem is, our bodies have not been conditioned to be eating all the time. Agriculture only came around about 10,000 years ago. The refrigerator only appeared early this century. We might be bigger, but not necessarily healthier. What then about increases in ailments like osteoporosis, cancer, heart disease, and diabetes? But thats besides the point, even though obesity due to overeating is a major cause of todays ailments.

Eating too much, too often, leads to lowered HGH levels simply because of the increase in insulin required to convert all that blood sugar into proper glycogen stores. Although Ill talk about this in future again, suffice to say, that insulin and HGH dont quite get along. When one is up, the other is down.

When you fast, your body has no reason to produce insulin, therefore it is primed to produce growth hormone. In other words, low insulin levels make for a conducive environment for HGH to be released. Fasting is a very effective means of increasing HGH levels.

But of course fasting also:

Our foods contain a lot of toxins, preservatives, pesticides and other unwanted stuff. These external ingredients accumulate within the body over time. A good fasting program done regularly, should help the body loosen and flush them away.

It may well be that the raise in HGH levels due to controlled food deprivation is what enables the body to actually live a longer lifespan. So, go ahead and try controlled fasting from time to time. If possible, combine that with meditation. Your body and mind will thank you for it.

Go here to read the rest:
Fasting and HGH HGH Talk

Read More..

A recent study published in the journal Mechanisms of Aging and Development confirms the "anti-aging" effect of high-intensity training.

Telomere shortening occurs as you age, however the factors involved are not entirely understood as of yet. The study was conducted to determine whether age-associated telomere shortening is related to habitual endurance exercise and maximal aerobic capacity.

The results suggest there's a direct association between reduced telomere shortening in your later years and high-intensity-type exercises.

The authors' state:

"The results of the present study provide evidence that leukocyte telomere length (LTL) is related to regular vigorous aerobic exercise and maximal aerobic exercise capacity with aging in healthy humans.

LTL is not influenced by aerobic exercise status among young subjects, presumably because TL is intact (i.e., already normal) in sedentary healthy young adults.

However, as LTL shortens with aging it appears that maintenance of aerobic fitness, produced by chronic strenuous exercise and reflected by higher VO2max, acts to preserve LTL.

Our results indicate that leukocyte telomere length (LTL) is preserved in healthy older adults who perform vigorous aerobic exercise and is positively related to maximal aerobic exercise capacity. This may represent a novel molecular mechanism underlying the "anti-aging" effects of maintaining high aerobic fitness."

But that's not all.

High-intensity interval-type training also boosts human growth hormone (HGH) production. A 2003 study published in the journal Sports Medicine found that "exercise intensity above lactate threshold and for a minimum of 10 minutes appears to elicit the greatest stimulus to the secretion of HGH."

Read the original:
Sprint 8 Exercises Increase Your "Fitness Hormone" Levels

Read More..

Investors watching recent action on shares of Hartford Financial Services Group Inc (HGH) may be looking to check in on some technical levels. Keeping an eye on Moving Averages, the 50-day is 31.16, the 200-day is at 30.70, and the 7-day is 30.79. Using the moving average for technical equity analysis is still very popular among traders and investors. The moving average can be used as a reference point to help discover buying and selling opportunities. Using a longer term moving average such as the 200-day may help block out the noise and chaos that is sometimes created by daily price fluctuations. In some cases, MAs may be used as strong reference points for finding support and resistance levels.

Hartford Financial Services Group Inc (HGH)s Williams Percent Range or 14 day Williams %R currently sits at -84.95. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

Hartford Financial Services Group Inc (HGH) currently has a 14-day Commodity Channel Index (CCI) of -74.71. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Currently, the 14-day ADX for Hartford Financial Services Group Inc (HGH) is sitting at 18.62. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, the 14-day RSI is currently at 41.55, the 7-day stands at 38.78, and the 3-day is sitting at 36.76.

Investors may be looking for the next positive catalyst to create a solid breakout. Some may be wondering when the party will end, and it remains to be seen if excess and profit-taking rotation may create any pullbacks in the upcoming quarter. Investors may have to make a decision whether to ease-up or stay aggressive. Investors may also be closely watching winners and losers, especially in the technology sector. Understanding and researching the space may be highly important when managing the investment portfolio. The key for investors will be to try and locate the winners in the space and find the companies that are either creating new technology or adapting to it rapidly.

See original here:
Stock Trading Watch for Hartford Financial Services Group Inc (HGH) - Danville Daily

Read More..

Shares of Hartford Financial Services Group Inc (HGH) are nearing some key technical levels as the Rank Correlation indicator has trending higher over the past few sessions, nearing potential overbought territory. Crossing the 80 mark would suggestthat a chance of a reversal is increasing.

The Rank Correlation Index (RCI) is based on an analysis algorithm by Charles Spearman. It uses a combination of price change data and time change data to identify potential changes in market sentiment, thereby exposing turning points. Zero crossings are seen as buy and sell signals, with tops and bottoms yielding overbought and oversold information.

Investors also might be looking to track the ATR or Average True Range of the stock. Currently, Hartford Financial Services Group Inc (HGH) has a 14-day ATR of 0.30. The Average True Range is an investor tool used to measure stock volatility. The ATR is not used to figure out price direction, just to measure volatility. The ATR is an indicator developed by J. Welles Wilder. Wilder has developed multiple indicators that are still quite popular in todays investing landscape. The general interpretation of the ATR is the higher the ATR value, the higher the volatility.

The Williams Percent Range or Williams %R is another technical indicator worth checking out. Hartford Financial Services Group Inc (HGH) currently has a 14 day Williams %R of -87.10. The Williams %R fluctuates between 0 and -100 measuring whether a security is overbought or oversold. The Williams %R is similar to the Stochastic Oscillator except it is plotted upside-down. Levels above -20 may indicate the stock may be considered is overbought. If the indicator travels under -80, this may signal that the stock is oversold. Chart analysts may also use the indicator to project possible price reversals and to define trends.

The Average Directional Index or ADX is technical analysis indicator used to discern if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for Hartford Financial Services Group Inc (HGH) is 18.85. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend.

Traders may be leaning on technical stock analysis to help with investing decisions. Hartford Financial Services Group Inc (HGH) currently has a 14-day Commodity Channel Index (CCI) of -66.58. Despite the name, CCI can be used on other investment tools such as stocks. The CCI was designed to typically stay within the reading of -100 to +100. Traders may use the indicator to determine stock trends or to identify overbought/oversold conditions. A CCI reading above +100 would imply that the stock is overbought and possibly ready for a correction. On the other hand, a reading of -100 would imply that the stock is oversold and possibly set for a rally.

Traders are paying renewed attention to shares of Hartford Financial Services Group Inc (HGH). The current 14-day RSI is presently sitting at 40.91, the 7-day is 37.32, and the 3-day is 32.11. The RSI, or Relative Strength Index is a popular oscillating indicator among traders and investors. The RSI operates in a range-bound area with values between 0 and 100. When the RSI line moves up, the stock may be experiencing strength. The opposite is the case when the RSI line is heading lower. Different time periods may be used when using the RSI indicator. The RSI may be more volatile using a shorter period of time. Many traders keep an eye on the 30 and 70 marks on the RSI scale. A move above 70 is widely considered to show the stock as overbought, and a move below 30 would indicate that the stock may be oversold. Traders may use these levels to help identify stock price reversals.

Go here to see the original:
Chartists Hone In On Hartford Financial Services Group Inc (HGH)'s Rank Correlation Indicator - Geneva Journal

Read More..

MIAMI, Aug. 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO or the Company), reports business and financial results for the three and six months ended June 30, 2017.

Business Highlights

Sales force expansion for RAYALDEE underway. OPKO has made substantial progress in obtaining formulary access for RAYALDEE, with more than 68% of potential patient lives now covered under insurance plans. With the more extensive insurance coverage available, OPKO is continuing to expand its field-based sales force to 70 representatives from the original 35. Phase 2a trial for intravenously administered Factor VII-CTP and Phase 1 trial for subcutaneously administered Factor VII-CTP ongoing. These long-acting forms of Factor VII utilizing OPKOs CTP technology are expected to better support prophylaxis, provide easier administration and decrease dosing frequency for hemophilia patients. Enrollment for global pediatric Phase 3 hGH-CTP clinical trial continues and a Japanese pediatric registration trial for hGH-CTP is now underway.Clinical trials of Claros point-of-care (POC) prostate specific antigen (PSA) test completed and Premarket Approval (PMA) filing anticipated this fall. Analytic and clinical validation studies of OPKOs proprietary POC diagnostic test for PSA have been completed; PMA application to the FDA is planned for 4Q 2017. OPKO expects to begin an additional multicenter study of its POC testosterone test in late 2017 or early 2018, followed by a 510(k) submission to FDA. Initiation of five Phase 2 clinical trials anticipated in 2H 2017 and early 2018.

BioReference Laboratories is well positioned to accelerate revenue growth and expand operating margins through the second half of 2017 and 2018.

Financial Highlights

Conference Call and Webcast Information

OPKOs senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time today. The conference call dial in information is listed below. To access the webcast, please log on to the OPKO website at http://www.opko.com.

WHEN: Tuesday, August 8, 2017, 4:30 p.m. Eastern time.DOMESTIC DIAL-IN: (866) 634-2258 INTERNATIONAL DIAL-IN: (330) 863-3454PASSCODE: 65755948WEBCAST: http://investor.opko.com/events.cfm

For those unable to participate in the live conference call or webcast, a replay will be available beginning August 8, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 65755948. The replay can be accessed for a period of time on OPKOs website at http://investor.opko.com/events.cfm.

About OPKO Health, Inc.

OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88004, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in phase 2a. We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at http://www.opko.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, whether 4Kscore test utilization will continue to grow, our product development efforts and the expected benefits of our products, including whether our ongoing and future clinical trials will be successfully completed on a timely basis or at all and whether the data from any of our trials will support submission or approval, validation and/or reimbursement for our products, the expected timing for launch of our products in development, whether the data for hGH-CTP will support approval of a BLA, the expected timing of commencing and concluding our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, the timing of our regulatory submissions, our ability to market and sell any of our products in development, expectations about developing RAYALDEE for dialysis patients, our ability to obtain broad reimbursement coverage for the 4Kscore test, expectations regarding revenue growth and operating margins for BioReference for the remainder of 2017 and 2018, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as integration challenges for Bio-Reference, EirGen, Transition, and other acquired businesses, the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that the 4Kscore, RAYALDEE, Varubi, hGH-CTP, OPKO88003, OPK88004, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

CompanyOPKO Health, Inc.David Malina, 305-575-4100Investor Relationsdmalina@opko.com

LHAAnne Marie Fields, 212-838-3777afields@lhai.comorBruce Voss, 310-691-7100bvoss@lhai.com

Tables to Follow

OPKO Health, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(unaudited)(in millions)

View post:
OPKO Health Reports Second Quarter 2017 Business and Financial Results - GlobeNewswire (press release)

Read More..

Trading was light with 24K shares changing hands by the end of trading on Friday. Volume was down 58.05% under the stocks average daily volume.

In the market the company is trading unchanged by 0.42% percent from yesterdays close. Company chares are trading at $30.86 which is just under $31.22, the stocks 50 day moving average and which is slightly below the 200 day moving average of $30.98. The 50 day moving average went down $-0.36 or -1.16% and the 200 day average moved down $-0.12.

The Hartford Financial Services Group, Inc., launched on December 9, 1985, is a holding company for insurance and financial services subsidiaries. The Company, through its subsidiaries, provides property and casualty insurance, group life and disability products, and mutual funds and exchange-traded products to individual and business customers in the United States. The Businesss segments include Commercial Lines, Personal Lines, Property & Casualty Other Operations, Group Benefits, Mutual Funds, Talcott Resolution and Corporate. The Company administers life insurance and annuity products previously sold..

Read more from the original source:
Hartford Financial Services Gro (NYSE:HGH) Experiences Lighter than Average Trading Volume - First News 24

Read More..

Contact Us Today

Page 1,854«..1020..1,8531,8541,8551,856..1,8601,870..»

Home » Page 1854